LA
JOLLA, Calif., Nov. 21,
2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica"
or the "Company") (Nasdaq: CALC), a clinical-stage
biopharmaceutical company focused on developing novel calcium
release-activated calcium (CRAC) channel inhibition therapies for
acute and chronic inflammatory and immunologic illnesses, today
announced that Rachel Leheny, Ph.D.,
Chief Executive Officer, will present at the Piper Sandler
36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 9:10 a.m. ET/ 6:10 a.m.
PT.
A live webcast of the presentation can be accessed in the
"Upcoming Events" section of CalciMedica's IR website at
https://ir.calcimedica.com/. A replay of the webcast will be
archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic
diseases. CalciMedica's proprietary technology targets
the inhibition of CRAC channels to modulate the immune response and
protect against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™
has demonstrated positive and consistent clinical results in
multiple completed efficacy clinical trials. CalciMedica has
announced topline data for a Phase 2b
trial (called CARPO – NCT04681066) in patients with acute
pancreatitis (AP) and accompanying systemic inflammatory response
syndrome (SIRS) and completed a Phase 2 trial (called CARDEA
– NCT04345614) in patients with COVID pneumonia. The Company
is currently conducting a Phase 2 trial (called KOURAGE
– NCT06374797) in patients with acute kidney disease (AKI)
with associated acute hypoxemic respiratory failure (AHRF)
and continuing to support the ongoing Phase 1/2 trial (called CRSPA
– NCT04195347) in pediatric patients with asparaginase-induced
pancreatic toxicity (AIPT). CalciMedica was founded by
scientists from Torrey Pines Therapeutics and the Harvard CBR
Institute for Biomedical Research, and is headquartered in La
Jolla, CA. For more information, please
visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-302312144.html
SOURCE CalciMedica, Inc.
